We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 08, 2021

Health-Related Quality of Life in Patients With Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab vs Chemotherapy

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Health-Related Quality of Life in Patients With Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer Treated With First-Line Pembrolizumab Versus Chemotherapy (KEYNOTE-177): An Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Apr 01;[EPub Ahead of Print], T Andre, M Amonkar, JM Norquist, KK Shiu, TW Kim, BV Jensen, LH Jensen, CJA Punt, D Smith, R Garcia-Carbonero, I Sevilla, C De La Fouchardiere, F Rivera, E Elez, LA Diaz, T Yoshino, E Van Cutsem, P Yang, M Farooqui, DT Le

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading